Tomoki T. Nomakuchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Tomoki T. Nomakuchi has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
- Elizabeth J. Bhoj
Department of Genetics, Perelman School of Medicine, University of Pennsylvania , Philadelphia, 19104
5 shared publications Dong Li
4 shared publications- Adrian R. Krainer
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA
3 shared publications - Andrew K. Sobering
Department of Biochemistry St. George's University School of Medicine St. George's Grenada
3 shared publications Beverly Nelson
2 shared publicationsDanielle E. Jolly
2 shared publications
Latest Publications
- 13 October 2026
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 113 (11) , 2363-2373
De novo MAP2K4 variants cause a neurodevelopmental syndrome and impaired JNK signaling in iPSC-derived neurons
- 13 October 2026
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 113 (11) , 2363-2373
De novo MAP2K4 variants cause a neurodevelopmental syndrome and impaired JNK signaling in iPSC-derived neurons
- 25 May 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 195 (3) , 473-482
Loss-of-function variants in EPHX3 cause nonsyndromic epidermal differentiation disorders
Background: Epidermal differentiation disorders (EDDs) are inherited keratinization disorders with remarkable clinical and genetic heterogeneity. Defects in epidermal lipid metabolism and corneocyte lipid envelope assembly account for a subset of EDDs. Epoxide hydrolase 3 (EH3), encoded by EPHX3, mediates the hydrolysis of linoleate-derived lipid epoxides during barrier formation. While Ephx3-deficient mice exhibit impaired skin barrier function, no human disorders caused by EPHX3 variants have been reported to date. Objectives: To determine the genetic basis of a new subtype of nonsyndromic EDD (nEDD) presenting from early infancy with generalized erythematous patches and plaques, xerosis and skin peeling; and to assess the impact of EH3 deficiency on epidermal lipid processing. Methods: Whole-exome sequencing was performed in three unrelated families with nEDDs to investigate the underlying genetic causes. The skin biopsy from one representative patient was analysed using immunofluorescence staining and lipid staining. Liquid chromatography–mass spectrometry was used to quantify EH3 activity. Patient-derived primary keratinocytes were used to generate three-dimensional (3D) skin equivalents to assess epidermal differentiation. Results: Three affected individuals from Chinese, Pakistani Irish and Russian families with nEDDs were enrolled. Biallelic EPHX3 variants (c.74G>A, p.Trp25*; c.289G>T, p.Gly97*; c.524G>A, p.Gly175Asp; c.908G>A, p.Trp303*; c.1033delC, p.Gln345Argfs*51) were identified in the patients. Total trihydroxyoctadecenoic acid was reduced in tape-stripping stratum corneum extracts from affected individuals, suggesting reduced EH3-dependent epoxide hydrolysis in vivo. Consistently, carriers of EPHX3 variants showed markedly reduced epoxide hydrolase activity in vitro. Nile red staining of the patient’s skin lesion revealed reduced and redistributed lipids, suggesting a disturbed stratum corneum lipid barrier. The patient’s keratinocyte-constructed 3D skin equivalent showed disrupted stratum corneum, more extensive keratin 1, increased loricrin and Ki-67, and reduced claudin-1 staining. Conclusions: We report biallelic loss-of-function EPHX3 variants causing a new subtype of nEDD. Our study also supports an important role of EH3-dependent epoxide hydrolysis in epidermal barrier lipid processing.
- 25 May 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 195 (3) , 473-482
Loss-of-function variants in EPHX3 cause nonsyndromic epidermal differentiation disorders
Background: Epidermal differentiation disorders (EDDs) are inherited keratinization disorders with remarkable clinical and genetic heterogeneity. Defects in epidermal lipid metabolism and corneocyte lipid envelope assembly account for a subset of EDDs. Epoxide hydrolase 3 (EH3), encoded by EPHX3, mediates the hydrolysis of linoleate-derived lipid epoxides during barrier formation. While Ephx3-deficient mice exhibit impaired skin barrier function, no human disorders caused by EPHX3 variants have been reported to date. Objectives: To determine the genetic basis of a new subtype of nonsyndromic EDD (nEDD) presenting from early infancy with generalized erythematous patches and plaques, xerosis and skin peeling; and to assess the impact of EH3 deficiency on epidermal lipid processing. Methods: Whole-exome sequencing was performed in three unrelated families with nEDDs to investigate the underlying genetic causes. The skin biopsy from one representative patient was analysed using immunofluorescence staining and lipid staining. Liquid chromatography–mass spectrometry was used to quantify EH3 activity. Patient-derived primary keratinocytes were used to generate three-dimensional (3D) skin equivalents to assess epidermal differentiation. Results: Three affected individuals from Chinese, Pakistani Irish and Russian families with nEDDs were enrolled. Biallelic EPHX3 variants (c.74G>A, p.Trp25*; c.289G>T, p.Gly97*; c.524G>A, p.Gly175Asp; c.908G>A, p.Trp303*; c.1033delC, p.Gln345Argfs*51) were identified in the patients. Total trihydroxyoctadecenoic acid was reduced in tape-stripping stratum corneum extracts from affected individuals, suggesting reduced EH3-dependent epoxide hydrolysis in vivo. Consistently, carriers of EPHX3 variants showed markedly reduced epoxide hydrolase activity in vitro. Nile red staining of the patient’s skin lesion revealed reduced and redistributed lipids, suggesting a disturbed stratum corneum lipid barrier. The patient’s keratinocyte-constructed 3D skin equivalent showed disrupted stratum corneum, more extensive keratin 1, increased loricrin and Ki-67, and reduced claudin-1 staining. Conclusions: We report biallelic loss-of-function EPHX3 variants causing a new subtype of nEDD. Our study also supports an important role of EH3-dependent epoxide hydrolysis in epidermal barrier lipid processing.
- Open Access
- 28 April 2026
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 14 (5)
Cover Image
- 28 April 2026
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 14 (5)
Open AccessCover Image
- Open Access
- 23 April 2026
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 14 (5) , e70216
Clinical and Neurodevelopmental Course in a Case of EFNB1 ‐Related Craniofrontonasal Syndrome With Unrepaired Craniosynostosis
Introduction: Craniofrontonasal syndrome displays an unusual X‐linked dominant inheritance pattern due to pathogenic variants in EFNB1 , which encodes a membrane‐bound ligand for the ephrin receptor. Females exhibit a more severe phenotype than males and can have craniosynostosis, hypertelorism, craniofacial asymmetry, thoracic skeleton abnormalities, and an assortment of other features. Males typically only develop a milder hypertelorism, or they have no discernable features at all. Methods: Exome sequencing was used to identify a likely pathogenic EFNB1 c.129‐2A>G splice site variant in an individual who had facial dysmorphology. Results: We describe a 14‐year‐old female from an underserved Caribbean population who had facial dysmorphology, microcephaly, and mild intellectual disability. She also had an uncorrected craniosynostosis that was diagnosed during clinical examination. Conclusion: The craniofrontonasal syndrome in the individual presented in this report is explained by the EFNB1 variant. The affected individual did not have surgical correction of her craniosynostosis, which might have contributed to her development of microcephaly and mild intellectual disability.
- 23 April 2026
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 14 (5) , e70216
Open AccessClinical and Neurodevelopmental Course in a Case of EFNB1 ‐Related Craniofrontonasal Syndrome With Unrepaired Craniosynostosis
Introduction: Craniofrontonasal syndrome displays an unusual X‐linked dominant inheritance pattern due to pathogenic variants in EFNB1 , which encodes a membrane‐bound ligand for the ephrin receptor. Females exhibit a more severe phenotype than males and can have craniosynostosis, hypertelorism, craniofacial asymmetry, thoracic skeleton abnormalities, and an assortment of other features. Males typically only develop a milder hypertelorism, or they have no discernable features at all. Methods: Exome sequencing was used to identify a likely pathogenic EFNB1 c.129‐2A>G splice site variant in an individual who had facial dysmorphology. Results: We describe a 14‐year‐old female from an underserved Caribbean population who had facial dysmorphology, microcephaly, and mild intellectual disability. She also had an uncorrected craniosynostosis that was diagnosed during clinical examination. Conclusion: The craniofrontonasal syndrome in the individual presented in this report is explained by the EFNB1 variant. The affected individual did not have surgical correction of her craniosynostosis, which might have contributed to her development of microcephaly and mild intellectual disability.
- Open Access
- 29 April 2025
- Published by Wiley in American Journal of Medical Genetics Part A
- p. e64095
Two New Cases Expand the Phenotypic Spectrum of TUBG1 Missense Variants
The gamma‐tubulin ring complex (γ‐TuRC) plays a role in coordinating centrosome and spindle pole body formation during cell division. TUBG1 encodes a critical component of the γ‐TuRC. Pathogenic TUBG1 variants can cause a range of alterations in cortical gyral patterning, microcephaly, and other neurological manifestations. We describe two missense variants in TUBG1 and their associated clinical phenotypes. One individual has microcephaly, epilepsy, and a simplified gyral pattern with a TUBG1 variant interpreted as pathogenic. The other individual has a likely pathogenic TUBG1 variant that explains the milder presentation of autism spectrum disorder, intellectual disability, later‐onset well‐controlled epilepsy, a normocephalic head size, and no detectable structural abnormalities on neuroimaging.
- 29 April 2025
- Published by Wiley in American Journal of Medical Genetics Part A
- p. e64095
Open AccessTwo New Cases Expand the Phenotypic Spectrum of TUBG1 Missense Variants
The gamma‐tubulin ring complex (γ‐TuRC) plays a role in coordinating centrosome and spindle pole body formation during cell division. TUBG1 encodes a critical component of the γ‐TuRC. Pathogenic TUBG1 variants can cause a range of alterations in cortical gyral patterning, microcephaly, and other neurological manifestations. We describe two missense variants in TUBG1 and their associated clinical phenotypes. One individual has microcephaly, epilepsy, and a simplified gyral pattern with a TUBG1 variant interpreted as pathogenic. The other individual has a likely pathogenic TUBG1 variant that explains the milder presentation of autism spectrum disorder, intellectual disability, later‐onset well‐controlled epilepsy, a normocephalic head size, and no detectable structural abnormalities on neuroimaging.
- Open Access
- 19 July 2024
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 194 (12) , e63817
Utility of genome sequencing in exome‐negative pediatric patients with neurodevelopmental phenotypes
Exome sequencing (ES) has emerged as an essential tool in the evaluation of neurodevelopmental disorders (NDD) of unknown etiology. Genome sequencing (GS) offers advantages over ES due to improved detection of structural, copy number, repeat number and non‐coding variants. However, GS is less commonly utilized due to higher cost and more intense analysis. Here, we present nine cases of pediatric NDD that were molecularly diagnosed with GS between 2017 and 2022, following non‐diagnostic ES. All individuals presented with global developmental delay or regression. Other features present in our cohort included epilepsy, white matter abnormalities, brain malformation and dysmorphic features. Two cases were diagnosed on GS due to newly described gene‐disease relationship or variant reclassification (MAPK8IP3, CHD3). Additional features missed on ES that were later detected on GS were: intermediate‐size deletions in three cases who underwent ES that were not validated for CNV detection, pathogenic variants within the non‐protein coding genes SNORD118 and RNU7‐1, pathogenic variant within the promoter region of GJB1, and a coding pathogenic variant within BCAP31 which was not sufficiently covered on ES. GS following non‐diagnostic ES led to the identification of pathogenic variants in this cohort of nine cases, four of which would not have been identified by reanalysis alone.
- 19 July 2024
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 194 (12) , e63817
Open AccessUtility of genome sequencing in exome‐negative pediatric patients with neurodevelopmental phenotypes
Exome sequencing (ES) has emerged as an essential tool in the evaluation of neurodevelopmental disorders (NDD) of unknown etiology. Genome sequencing (GS) offers advantages over ES due to improved detection of structural, copy number, repeat number and non‐coding variants. However, GS is less commonly utilized due to higher cost and more intense analysis. Here, we present nine cases of pediatric NDD that were molecularly diagnosed with GS between 2017 and 2022, following non‐diagnostic ES. All individuals presented with global developmental delay or regression. Other features present in our cohort included epilepsy, white matter abnormalities, brain malformation and dysmorphic features. Two cases were diagnosed on GS due to newly described gene‐disease relationship or variant reclassification (MAPK8IP3, CHD3). Additional features missed on ES that were later detected on GS were: intermediate‐size deletions in three cases who underwent ES that were not validated for CNV detection, pathogenic variants within the non‐protein coding genes SNORD118 and RNU7‐1, pathogenic variant within the promoter region of GJB1, and a coding pathogenic variant within BCAP31 which was not sufficiently covered on ES. GS following non‐diagnostic ES led to the identification of pathogenic variants in this cohort of nine cases, four of which would not have been identified by reanalysis alone.
- Open Access
NeuroTri2-VISDOT: An open-access tool to harness the power of second trimester human single cell data to inform models of Mendelian neurodevelopmental disorders
Whole exome and genome sequencing, coupled with refined bioinformatic pipelines, have enabled improved diagnostic yields for individuals with Mendelian conditions and have led to the rapid identification of novel syndromes. For many Mendelian neurodevelopmental disorders (NDDs), there is a lack of pre-existing model systems for mechanistic work. Thus, it is critical for translational researchers to have an accessible phenotype- and genotype-informed approach for model system selection. Single-cell RNA sequencing data can be informative in such an approach, as it can indicate which cell types express a gene of interest at the highest levels across time. For Mendelian NDDs, such data for the developing human brain is especially useful. A valuable single-cell RNA sequencing dataset of the second trimester developing human brain was produced by Bhaduri et al in 2021, but access to these data can be limited by computing power and the learning curve of single-cell data analysis. To reduce these barriers for translational research on Mendelian NDDs, we have built the web-based tool, Neuro development in Tri mester 2 - VI sualization of S ingle cell D ata O nline T ool (NeuroTri2-VISDOT), for exploring this single-cell dataset, and we have employed it in several different settings to demonstrate its utility for the translational research community.
Open AccessNeuroTri2-VISDOT: An open-access tool to harness the power of second trimester human single cell data to inform models of Mendelian neurodevelopmental disorders
Whole exome and genome sequencing, coupled with refined bioinformatic pipelines, have enabled improved diagnostic yields for individuals with Mendelian conditions and have led to the rapid identification of novel syndromes. For many Mendelian neurodevelopmental disorders (NDDs), there is a lack of pre-existing model systems for mechanistic work. Thus, it is critical for translational researchers to have an accessible phenotype- and genotype-informed approach for model system selection. Single-cell RNA sequencing data can be informative in such an approach, as it can indicate which cell types express a gene of interest at the highest levels across time. For Mendelian NDDs, such data for the developing human brain is especially useful. A valuable single-cell RNA sequencing dataset of the second trimester developing human brain was produced by Bhaduri et al in 2021, but access to these data can be limited by computing power and the learning curve of single-cell data analysis. To reduce these barriers for translational research on Mendelian NDDs, we have built the web-based tool, Neuro development in Tri mester 2 - VI sualization of S ingle cell D ata O nline T ool (NeuroTri2-VISDOT), for exploring this single-cell dataset, and we have employed it in several different settings to demonstrate its utility for the translational research community.
- 13 March 2023
- Published by Georg Thieme Verlag KG in Neuropediatrics
- Vol. 55 (01) , 071-074
Subdural Hemorrhage as an Early Presentation in a Case of Sotos Syndrome
Subdural hemorrhages (SDHs) in the pediatric population are associated with a high mortality and morbidity and may present in the context of abusive head trauma. Diagnostic investigations for such cases often include evaluation for rare genetic and metabolic disorders that can have associated SDH. Sotos syndrome is an overgrowth syndrome associated with macrocephaly and increased subarachnoid spaces and rarely with neurovascular complications. Here, we report two cases of Sotos syndrome, one with SDH during infancy who underwent repeated evaluation for suspected child abuse prior to the Sotos syndrome diagnosis and the other with enlarged extra-axial cerebrospinal fluid spaces, demonstrating a possible mechanism for SDH development in this setting. These cases suggest that some individuals with Sotos syndrome may be at elevated risk of developing SDH in infancy and that Sotos syndrome should be on the differential diagnosis during a medical genetics evaluation in cases of unexplained SDH, especially in the setting of macrocephaly.
- 13 March 2023
- Published by Georg Thieme Verlag KG in Neuropediatrics
- Vol. 55 (01) , 071-074
Subdural Hemorrhage as an Early Presentation in a Case of Sotos Syndrome
Subdural hemorrhages (SDHs) in the pediatric population are associated with a high mortality and morbidity and may present in the context of abusive head trauma. Diagnostic investigations for such cases often include evaluation for rare genetic and metabolic disorders that can have associated SDH. Sotos syndrome is an overgrowth syndrome associated with macrocephaly and increased subarachnoid spaces and rarely with neurovascular complications. Here, we report two cases of Sotos syndrome, one with SDH during infancy who underwent repeated evaluation for suspected child abuse prior to the Sotos syndrome diagnosis and the other with enlarged extra-axial cerebrospinal fluid spaces, demonstrating a possible mechanism for SDH development in this setting. These cases suggest that some individuals with Sotos syndrome may be at elevated risk of developing SDH in infancy and that Sotos syndrome should be on the differential diagnosis during a medical genetics evaluation in cases of unexplained SDH, especially in the setting of macrocephaly.
- 16 February 2023
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 191 (5) , 1418-1424
Expanding the reproductive organ phenotype of CHD7‐spectrum disorder
CHD7 disorder is a multiple congenital anomaly syndrome with a highly variable phenotypic spectrum, and includes CHARGE syndrome. Internal and external genital phenotypes frequently seen in CHD7 disorder include cryptorchidism and micropenis in males, and vaginal hypoplasia in females, both thought to be secondary to hypogonadotropic hypogonadism. Here, we report 14 deeply phenotyped individuals with known CHD7 variants (9 pathogenic/likely pathogenic and 5 VOUS) and a range of reproductive and endocrine phenotypes. Reproductive organ anomalies were observed in 8 of 14 individuals and were more commonly noted in males (7/7), most of whom presented with micropenis and/or cryptorchidism. Kallmann syndrome was commonly observed among adolescents and adults with CHD7 variants. Remarkably, one 46,XY individual presented with ambiguous genitalia, cryptorchidism with Mullerian structures including uterus, vagina and fallopian tubes, and one 46,XX female patient presented with absent vagina, uterus and ovaries. These cases expand the genital and reproductive phenotype of CHD7 disorder to include two individuals with genital/gonadal atypia (ambiguous genitalia), and one with Mullerian aplasia.
- 16 February 2023
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 191 (5) , 1418-1424
Expanding the reproductive organ phenotype of CHD7‐spectrum disorder
CHD7 disorder is a multiple congenital anomaly syndrome with a highly variable phenotypic spectrum, and includes CHARGE syndrome. Internal and external genital phenotypes frequently seen in CHD7 disorder include cryptorchidism and micropenis in males, and vaginal hypoplasia in females, both thought to be secondary to hypogonadotropic hypogonadism. Here, we report 14 deeply phenotyped individuals with known CHD7 variants (9 pathogenic/likely pathogenic and 5 VOUS) and a range of reproductive and endocrine phenotypes. Reproductive organ anomalies were observed in 8 of 14 individuals and were more commonly noted in males (7/7), most of whom presented with micropenis and/or cryptorchidism. Kallmann syndrome was commonly observed among adolescents and adults with CHD7 variants. Remarkably, one 46,XY individual presented with ambiguous genitalia, cryptorchidism with Mullerian structures including uterus, vagina and fallopian tubes, and one 46,XX female patient presented with absent vagina, uterus and ovaries. These cases expand the genital and reproductive phenotype of CHD7 disorder to include two individuals with genital/gonadal atypia (ambiguous genitalia), and one with Mullerian aplasia.
- Open Access
Gene-Specific Nonsense-Mediated mRNA Decay Targeting for Cystic Fibrosis Therapy
Low CFTR mRNA expression due to nonsense-mediated mRNA decay (NMD) is a major hurdle in developing a therapy for cystic fibrosis (CF) caused by the W1282X mutation in the CFTR gene. CFTR-W1282X truncated protein retains partial function, so increasing its levels by inhibiting NMD of its mRNA will likely be beneficial. Because NMD regulates the normal expression of many genes, gene-specific stabilization of CFTR-W1282X mRNA expression is more desirable than general NMD inhibition. Synthetic antisense oligonucleotides (ASOs) designed to prevent binding of exon junction complexes (EJC) downstream of premature termination codons (PTCs) attenuate NMD in a gene-specific manner. We developed a cocktail of three ASOs that specifically increases the expression of CFTR W1282X mRNA and CFTR protein in ASO-transfected human bronchial epithelial cells. This treatment increased the CFTR-mediated chloride current. These results set the stage for clinical development of an allele-specific therapy for CF caused by the W1282X mutation.
Open AccessGene-Specific Nonsense-Mediated mRNA Decay Targeting for Cystic Fibrosis Therapy
Low CFTR mRNA expression due to nonsense-mediated mRNA decay (NMD) is a major hurdle in developing a therapy for cystic fibrosis (CF) caused by the W1282X mutation in the CFTR gene. CFTR-W1282X truncated protein retains partial function, so increasing its levels by inhibiting NMD of its mRNA will likely be beneficial. Because NMD regulates the normal expression of many genes, gene-specific stabilization of CFTR-W1282X mRNA expression is more desirable than general NMD inhibition. Synthetic antisense oligonucleotides (ASOs) designed to prevent binding of exon junction complexes (EJC) downstream of premature termination codons (PTCs) attenuate NMD in a gene-specific manner. We developed a cocktail of three ASOs that specifically increases the expression of CFTR W1282X mRNA and CFTR protein in ASO-transfected human bronchial epithelial cells. This treatment increased the CFTR-mediated chloride current. These results set the stage for clinical development of an allele-specific therapy for CF caused by the W1282X mutation.